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ABSTRACT 
Nicotine is the major neurotoxicant in cigarettes that affects many transmitter systems within the 
brain as well as other factors, including the growth factors. Brain derived neurotrophic factor 
(BDNF), is the most abundant growth factor in the brain and plays a critical role in early new 
neuron differentiation, development and synapsis growth, and the survival of fully developed 
neurons and synaptic activity. Over the past 3 decades, data has emerged on the effects of nicotine 
and cigarette smoke exposure on the expression of BDNF and its primary specific receptor tyrosine 
kinase receptor B (TrkB). This review summarizes data regarding the changes in brain BDNF 
expression after nicotine or cigarette smoke exposure, and discusses their implications considering 
BDNF’s functional roles.   
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Introduction 
Brain derived neurotrophic factor (BDNF), is the most abundant neurotrophin growth factor in the 
brain and is important for cellular growth, development, survival and synaptic activity (Webster et 
al., 2002, reviewed Cunha et al., 2010). These actions are mediated via BDNF binding selectively 
to its tyrosine kinase receptor B (TrkB) receptor (Fayard et al., 2005). 
 
Cigarette smoke exposure is the leading modifiable health burden in many countries with an 
estimated 1.1 billion people smoking in 2015 (WHOa). The consequences are not only on the 
smokers themselves, but also to those around them via passive smoke exposure, responsible for 7 
million deaths per year, including 600,000 from second-hand smoking (WHOb).  In addition, 
smoking is particularly detrimental on the developing young brains if exposed during the 
gestational period where the effects could be long lasting well into adulthood by causing epigenetic 
changes (reviewed Poon and Leibowitz 2016).  
 
Our laboratory’s interest is on Sudden Infant Death Syndrome (SIDS), for which cigarette smoke 
exposure is currently the leading modifiable risk factor (Mitchell et al., 2012). This is despite health 
campaigns advising against it (Mitchell et al., 2012). Although many pregnant women aim to cease 
smoking during pregnancy, the success rate is low during gestation (Filion et al., 2011). In addition, 
the relapse rate is high particularly in the early post-natal period. A main hypothesis in SIDS is that 
it is a developmental disorder of the cardio-respiratory centres in the brainstem (Hunt 1992) and as 
such, death ensues during a sleep period of either or both a cardiac or respiratory compromising 
event. BDNF knockout mice show severe depression of respiratory frequency and minute 
ventilation, with a loss of the hypoxic ventilatory drive, and they die within the first two weeks of 
life (Balkowiec and Katz, 1998, Erickson et al., 1996, Ernfors et al., 1994). This made it a candidate 
marker for study in our laboratory within the context of SIDS (Tang et al., 2012).   
 
Nicotine, a main neuroactive component of cigarettes (tobacco), has been shown to directly induce 
changes in BDNF levels (Summarised in Table 2). In living humans, changes in BDNF are 
measured via serum or plasma given there is not yet a means to sensitively and accurately visualise 
and measure BDNF levels in the brain using imaging systems (Fukuchi et al., 2017). Despite this, 
evidence exists that peripheral (serum and plasma) BDNF levels do correlate with brain BDNF 
levels (Karege et al., 2002, Klein et al., 2011) and as such, can be used as surrogates of brain 
changes. That said, verification is advantageous and to this end, animal studies provide such 
assurance. Over the past three decades, many animal models of cigarette smoke and/or nicotine 
exposure have been developed and studied in relation to the effects on BDNF and TrkB expression 
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in the brain. This review will summarise these studies and aim to provide a mechanistic explanation 
for the changes observed.  
 
The BDNF System  
Growth factors are required for the normal development and functioning of the central nervous 
system. One family of growth factors is the neurotrophin family, which consists of nerve growth 
factor (NGF), BDNF, neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5). Neurotrophins are 
known for their roles during development and maintenance of the nervous system and have been 
detected as early as during embryonic development (reviewed in Bernd, 2008).  
 
All neurotrophins are synthesised as pre-pro-neurotrophin precursors (approximately 240-260 
amino acids long) within the rough endoplasmic reticulum and undergo several processes to convert 
into pro-neurotrophins and neurotrophins (Edwards et al., 1988; Seidah et al., 1996). Once formed 
they then accumulate in the membrane stacks of the trans-Golgi network and are secreted via two 
different types of secretory vesicles (constitutive or regulated) available for intracellular protein 
trafficking. The secretory vesicles are characterised according to their mechanism of secretion. The 
constitutive secretory vesicles release the neurotrophins in the absence of any specific triggering 
mechanism, whereas the regulated secretory vesicles release neurotrophins in an activity-dependent 
manner or in response to the stimuli, such as stress and hypoxia (reviewed by Cunha et al., 2010). 
Pro-neurotrophins not only promote the synthesis of neurotrophins, but can also act as ligands, with 
both often having opposing effects.   
 
BDNF Production  
As a neurotrophin, BDNF consists of two forms, pro and mature. Throughout the literature, the 
terms mature-BDNF, rh-BDNF, and BDNF are used interchangeably, but refer to the same form. 
Therefore in this review, the term BDNF will be used when referring to these. The pro- and mature- 
forms differ in function, primarily due to the neurotrophin receptors they activate. BDNF is 
generated from proBDNF by cleaving to extracellular proteinase plasmin (Pang et al., 2004) and 
undergoes N-terminal cleavage within the trans-Golgi network and/or immature secretory vesicles 
(Mowla et al., 2001). The intracellular conversion of proBDNF to BDNF is predominantly 
mediated by prohormone convertase (Seidah et al., 1996, Ullal et al., 2007). ProBDNF and BDNF 
play opposing roles by binding to two structurally unrelated receptors, the p75 neurotrophin 
receptor (p75NTR) and the TrkB, respectively (Chao, 2003; Patapoutian and Reichardt, 2001). 
ProBDNF through the activation of p75NTR facilitates apoptosis (Teng et al., 2005), whereas 
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BDNF through the activation of the TrkB receptor, promotes neuronal survival and axonal growth 
(Rose et al., 2004). 
 
Once formed, BDNF is stored in the nerve terminals (Luo et al., 2001) and secreted through the 
regulated secretory pathway in an activity-dependent manner. Activity-dependent release of BDNF 
may be triggered by direct activation of voltage-gated Na2+ channels, which requires both Ca2+ 
influx and mobilization of Ca2+ from intracellular stores (Balkowiec and Katz, 2002). BDNF is 
transported both retrogradely and anterogradely (Ernfors et al., 1994, Tonra, 1999, Zhou and Rush, 
1996). Anterograde transport is performed by sensory neurons towards both peripheral and central 
targets (Zhou and Rush, 1996), whereas the retrograde transport is used for target derived 




The cellular actions of BDNF are mediated through the activation of its receptors.  ProBDNF and 
BDNF bind selectively to TrkB and to p75NTR. BDNF binds to TrkB with high affinity and to 
p75NTR with low affinity, whereas proBDNF binds primarily to p75NTR and secondarily to TrkB, 
but not to TrkA or TrkC (Fayard et al., 2005). Given this review is focused on BDNF alone, the 
remainder of this section will only address TrkB. 
 
The activation of TrkB receptors is a two-step process; ligand-mediated oligomerization of receptor 
molecules at the cell surface, followed by autophosphorylation of their tyrosine residues in the 
cytoplasmic domain (Schlessinger and Ullrich, 1992, reviewed in Cunha et al., 2010). 
Autophosphorylation promotes recruitment of a series of intracellular proteins and triggers signal 
transduction pathways (Patapoutian and Reichardt, 2001). After BDNF binds to TrkB at the cell 
surface, Na+ channels open. Once this has taken place, phosphorylation of Trk kinase activates 
phospholipase C- (PLC-), resulting in,  
1- The formation of the second-messengers diacylglycerol and inositol 1,4,5 triphosphate (IP3) 
(Rose et al., 2004). IP3 induces the release of Ca2+ stores, increasing intracellular levels of 
Ca2+ thereby activating several pathways that are controlled by Ca2+ (Patapoutian and 
Reichardt, 2001), and;  
2- The opening of transient receptor potential ion 3 channels (TRPC3) which are located 
adjacent to the TrkB receptors, and causes an influx of Na+ and Ca2+ leading to the 
modulation of synaptic transmission (Rose et al., 2004, reviewed in Cunha et al., 2010, 
schematically provided Figure 1).  
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The deletion of TrkB via knockout technology reduces presynaptic and postsynaptic development, 
and electrophysiological responses. These effects indicate that TrkB has a role in excitatory 
synaptic formation (Luikart et al., 2005). TrkB knockout mice died within 24 to 48 hours of birth 
and this was attributed to their failure to feed due to abnormalities (predominantly increased 
apoptotic cell death (Alcañtara et al. 1997, Holm et al. 2003)) in the motor neural system involved 
in swallowing (Klein et al., 1993). This indicates the critical role of TrkB in survival and brain 
apoptotic regulation. Moreover, differential regulation of TrkB has been found in many 
neuropathological conditions across various age spectrums with downregulation generally observed 
in neuro-psychiatric, -degenerative and -dependent disorders, while upregulation is seen in tumour 
related disorders and tissue injury (reviewed Gupta et al., 2013). 
 
Physiological functions of BDNF  
BDNF is involved in the promotion of normal nervous system development, through promoting 
neurite growth and establishing synaptic connections between neurons and target cells (Cohen-
Cory, 2002), and via the interaction with other major neurotransmitter systems including 
glutamatergic, gabaergic, serotoninergic and dopaminergic (reviewed Changeux 2012, Autry and 
Montegia 2012). During development, high levels of BDNF expression are required for the normal 
development of the nervous system (Webster et al., 2002). Once the nervous system is developed, 
maintenance and stabilisation is promoted through the process of long-term potentiation (LTP). 
LTP is defined as “a stable, relatively long lasting increase in the magnitude of a post-synaptic 
response to a constant afferent volley following brief tetanic stimulation of the same afferents” 
(Teyler and DiScenna, 1987). Thus, it is where synaptic activity between brain cells occurs, leading 
to the formation of plasticity and memory (Ernfors and Bramham, 2003). BDNF has been shown to 
be important in promoting LTP (Korte et al., 1996) and the presence of BDNF can significantly 
improve LTP deficits in basal synaptic transmission in BDNF null mice (Patterson et al., 1996). The 
effects of BDNF on LTP are mediated by cAMP-response-element-binding protein (CREB) that 
regulates the expression of genes involved in the function of LTP (Ernfors and Bramham, 2003).  
 
Physiologically, identified through BDNF knockout (KO) mice models, BDNF is important for the 
regulation of: 
1- Respiration: BDNF KO mice showed severe depression of respiratory frequency and minute 
ventilation, with a loss of the hypoxic ventilatory drive (Balkowiec and Katz 1998, Erickson et 
al., 1996); 
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2- Coordination of movement and balance: BDNF KO mice had poor motor coordination and 
body balance (Conover et al., 1995); 
3- Survival during early postnatal period: BDNF KO mice failed to thrive beyond postnatal day 8 
(Conover et al., 1995, Ernfors et al., 1994, Jones et al., 1994).  
 
These functions were affected predominantly as a result of increased neuronal apoptosis (Bianchi et 
al. 1996, Ernfors et al., 1994, Patel and Krimm 2010), decreased differentiation (Jones et al., 1995), 
and deficits in synaptic function/ synaptogenesis (Korte et al., 1996, Patterson et al., 1996), 
particularly in the thalamus (Lotto et al. 2001), substantia nigra (Baker et al. 2005), cerebellum 
(Schwartz et al. 1997) and sensory ganglia that innervate the inner ear and vestibular system 
(Bianchi et al. 1996, Ernfors et al., 1994). The death of the BDNF KO mice during the early 
postnatal period is believed to be due to the increased death of sensory neurons in the petrosal and 
nodose ganglia (Jones et al., 1994), given they relay information from the heart, lungs, great blood 
vessels, and gut to the central nervous system. 
 
The expression and modulation of BDNF are regulated by various insults including stress, hypoxia, 
ischemia, seizure activity, temperature change, hypoglycaemia, and exposures to neurotoxic drugs 
(Reviewed in Tapia-Arancibia et al., 2004). Such changes in BNDF expression are also responsible 
for neurological conditions, such as anxiety, depression, epilepsy, Alzheimer’s and Parkinson’s 
disease. Indeed, abnormal immunostaining results of both BDNF and TrkB have been reported in 
the hippocampus of patients with schizophrenia (Iritani et al., 2003). This review will focus on the 
changes of BDNF and TrkB expression induced by nicotine exposure. 
 
Nicotine and nicotinic acetylcholine receptors (nAChRs) 
Nicotine is the major addictive and neurotoxic agent of cigarettes/tobacco (Dani and Heinemann 
1996, Benowitz 1996), and unlike many of the compounds present in tobacco smoke, has no major 
environmental sources other than tobacco. Nicotine dependence is more prevalent than dependence 
on any other substance of abuse (Markou 2008), especially when tobacco is legal to consume and 
sell compared with the other substances. Nicotine’s predominant effects are induced by activating 
the nAChRs. The nAChRs belong to the cys-loop family of ligand-gated ion channels that exist as 
pentamers of subunits, arranged symmetrically around a central pore (Cooper et al., 1991). A total 
of seventeen subunits (1-10, β1-4, , γ and δ) have been identified, and all subunits are of 
mammalian origin with the exception of 8 which is avian (Papke et al., 2008). nAChRs are found 
at skeletal neuromuscular junctions and autonomic ganglia as either homopentamers or 
heteropentamers. Within the central nervous system, the predominant conformation of these 
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subunits is heteromeric, although 7 and 9 homopentamers exist. The 7 homomeric and α4β2 
heteromeric nAChRs are the two main types widely expressed throughout the whole brain with the 
α7 nAChRs characterized by a fast activation, low affinity and high Ca
2+
 permeability while the 
α4β2 are characterised by a high affinity and slow desensitization. The expression of other nAChR 
subunits are more restricted within the brain (Reviewed Gotti and Clementi 2004). 
 
Normal synaptic activity in the brain relies on the nAChRs via their response to endogenous 
acetylcholine (ACh), and have been implicated in physiological functions such as sleep, fatigue, 
anxiety, the central processing of pain, food intake and a number of cognitive functions (Role and 
Berg, 1996, Gotti et al., 1997, Lindstrom, 1997). However, abnormal (either excessive or deficient) 
ACh innervation of the nAChRs can lead to various diseases throughout the life span including 
frontal lobe epilepsy (Steinlein, 2000), schizophrenia (Freedman et al., 2000) and Alzheimer’s 
disease (Wang et al., 2000).  
 
The activation of brain nAChRs by nicotine also results in abnormal synaptic activity and changed 
neuropathology (reviewed in Slotkin, 1998), including addiction, increased apoptosis (cell death) 
(Trauth et al., 2000, Machaalani and Waters, 2005), and abnormal expressions of neurotransmitters 
and their receptors such as glutamate (Fanous et al., 2006), serotonin (Say et al., 2007), orexin 
(reviewed by Machaalani et al., 2016), and dopamine (Slotkin, 1998). The latter is thought to be 
associated with increased endorphin levels and increased addiction to nicotine. Moreover, a direct 
change in the expression (Browne et al., 2010, Vivekanandarajah et al., 2015, Vivekanandarajah et 
al., 2016) and functions (Sparks and Pauly, 1999, Buisson and Bertrand, 2001) of the nAChRs 
occur in response to nicotine exposures. 
 
Human studies of nicotine on BDNF and TrkB 
The majority of the human studies of nicotine’s effects on BDNF involve DNA genotyping for 
BDNF SNP variants. Such studies where adult smokers were genotyped found several associations 
between allelic variations of BDNF and nicotine dependence, yet some variations were evident  
according to sex and ethnicity  (Beuten et al., 2005, Lang et al., 2007, Zhang et al., 2012, 2015, 
2016). Two other studies extended the analysis into the offspring of smoking mothers and found the 
associations between BDNF SNP variants and addiction were indeed present in adolescents 
(Toledo-Rodriguez et al. 2010, Lotfipour et al., 2009). Such adolescent offspring had a 1.5-fold 
increase in substance abuse (Lotfipour et al., 2009). Only one study has looked at the effects of 
nicotine exposure on TrkB in humans and this study was also a genotype study of 9 SNPs within 
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the TrkB gene (NTRK2). An association between the allelic variants of NTRK2 and three nicotine 
dependence measures were found in European-American smokers (Beuten et al., 2007). 
 
Given the limitations in directly studying brain BDNF in living humans, BDNF levels have 
primarily been studied in the periphery, via serum or plasma. Peripheral BDNF is highly 
concentrated in the platelets (Fujimura et al., 2002), with serum having approximately 50–200-fold 
higher levels than the plasma (Radka et al., 1996, Rosenfeld et al., 1995). This difference is 
suggested to reflect the release of BDNF from platelets during blood clotting (Fujimura et al., 
2002). This could also explain why BDNF levels were found to vary according to diurnal rhythm in 
plasma but not in serum (Piccinni et al., 2008), and to decrease with aging or weight gain in plasma 
but not in platelets or serum (Lommatzsch et al., 2005). Regarding brain levels, derived from 
animal studies, peripheral and brain BDNF levels do correlate, yet this was species dependent; yes 
in the rat and pig, but no in the mouse (Karege et al., 2002, Klein et al., 2011). However, Klein et 
al., 2011 suggest that the lack of any trace of BDNF in mouse blood may not be a true finding, but 
rather due to the low sensitivity of the commercially available ELISA kit. This is based on the 
finding that mice readily transport iodine-labelled BDNF and recombinant BDNF in the blood (Pan 
et al. 1998). Nevertheless, based on the strong evidence from the studies in the rat and pig, it can be 
extrapolated that peripheral (serum and plasma) measures of BDNF in the human would be 
representative of brain levels.  
 
To date, six studies have been conducted in humans to determine the effects of nicotine (via 
cigarette smoking) on peripheral BDNF levels (summarised in Table 1). From these studies, the 
predominant direction of change due to nicotine exposure is increased BDNF (Zhang et al., 2010, 
Suriyaprom et al., 2013, Jamal et al., 2015, Neves et al., 2017). The initial two studies performed by 
Kim et al. and Bhang et al. were performed on plasma with relatively small sample size and showed 
that healthy adult smokers had decreased plasma BDNF than the non-smokers; when smoking was 
ceased for > 4 weeks, BDNF levels increased to the non-smoker’s levels or above (Kim et al., 2007, 
Bhang et al., 2010). The subsequent studies performed on serum with larger sample size showed 
that both schizophrenic (Zhang et al., 2010) and healthy adults (Suriyaprom et al., 2013, Jamal et 
al., 2015, Neves et al., 2017) had increased serum BDNF levels and this was associated /correlated 
with the amount and duration of cigarette smoking and blood cortisol levels, but not with the BDNF 
Val66Met genotype (Suriyaprom et al., 2013). Combined, these studies provide strong evidence 
that nicotine exposure in humans affects BDNF expression and this is most likely to be a 
consequence of the changes in brain BDNF levels, something that animal studies have helped to 
clarify as discussed in the next section. 
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Our laboratory was the first to report BDNF and TrkB expression in the human infant brain 
(brainstem and hippocampus) (Tang et al., 2010) and subsequently to report the effects of cigarette 
smoke exposure amongst these infants, for whom the predominating diagnosis was Sudden Infant 
Death Syndrome (SIDS) (Tang et al., 2011). We found that infants for whom, at the time of death, 
the parents had indicated a positive history of cigarette smoke exposure (be it the mother, father, 
both or any other household member), no change in BDNF expression was observed in the 
brainstem nuclei studied, yet an increase in proBDNF and decrease in TrkB was evident in the 
hypoglossal and vestibular nuclei, both having a role in respiratory control (Tang et al., 2011). A 
subsequent study from another laboratory showed that in the kolliker-fuse nucleus (also important 
for respiratory control), altered BDNF expression was evident amongst infants with cigarette smoke 
exposure (Lavezzi et al., 2014) and this was extended into the cerebellum showing decreased 
BDNF levels in both brain regions (Lavezzi et al., 2018). Combined, these studies provide the first 
reports that exposure of the developing human to pre- and/or postnatal cigarette smoke alters BDNF 
and TrkB expression in respiratory regulating regions and could have played a role in subsequent 
pathophysiology changes leading to death. 
 
Animal models of nicotine and cigarette smoke exposure  
Given the limitations of studying brain BDNF in humans, animal studies are developed to provide 
the much needed data. With regards to nicotine exposure, to ensure the animals are receiving doses 
that equate to human consumption, measures of either nicotine or cotinine levels in the blood or 
urine are performed, with measurement of cotinine preferred given its longer half life (16 hours 
versus 2 hours for nicotine)(Benowitz and Jacob, 1993). The metabolism, distribution and excretion 
rate of nicotine differs with species, hence slight variations would be anticipated (Bramer and 
Kallungal 2003). To mimic childhood and adult cigarette smoke exposure paradigms, doses should 
be approximately 6mg/kg/day to produce cotinine levels indicative of active smoking which is 
>220ng/ml or 100nmol/L in serum and >3516ng/ml or 1,700nmol/L in urine (Vine et al., 1993, 
SSWPS Handbook 2014). For early postnatal exposure, as would be experienced by babies through 
breast milk or environmental passive smoke exposure, the dose should be within 2-4mg/kg/day 
resulting in plasma and urine cotinine levels >5ng/ml and >10ng/ml respectively (Luck and Nau, 
1985). For maternal (prenatal) cigarette smoke exposure, doses should be within 2-6mg/kg/day, 
resulting in plasma cotinine levels of >100ng/ml (Murrin et al., 1987, Lichtensteiger et al., 1988).  
 
The mode of administration is another consideration when developing the animal model of nicotine 
exposure. The common methods to date include: gavage, injection (intraperitoneal or 
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subcutaneous), infusion, osmotic minipump infusion, dermal patches or placing the animal in a 
cigarette smoke exposure chamber. Current studies lean towards the use of minipumps and nicotine 
patches given they result in steady states of plasma nicotine levels and overcome the hypoxia-
ischemia effects which were seen to occur when using the injection method (Slotkin 1998). A 
recent review addressing the various animal models of nicotine exposure and their results is 
provided by Cohen and George 2013. 
 
Nicotine exposure on BDNF expression in the brain from animal studies (Table 2). 
The baseline expression of BDNF has been extensively studied amongst species including the rat 
pup, (Hafidi et al., 1999), piglet (Pieris et al., 2004, Tang et al., 2008), gerbil (Tierney et al., 2001), 
adult rat (Hafidi et al., 1999, Kawamoto et al., 1996, Yan et al., 1997), adult monkey (Kawamoto et 
al., 1999, Zhang et al., 2007), human infant (Tang et al., 2010, Tang et al., 2011), and human adult 
(Murer et al., 1999, Tang et al., 2010).  
 
To date, a modest number of studies have examined the effects of nicotine or cigarette smoke 
exposure, both prenatally and postnatally, on the expression of BDNF within the brain (summarized 
Table 2). Majority of the studies in Table 2 were conducted in the rat and mouse with the exception 
of our own study in piglets (Tang et al., 2008). Moreover, the majority focused on the male sex and 
adult age. It is only recently (since 2011) that studies have commenced to look at the effects of 
prenatal nicotine exposure on BDNF expression in the offspring (Table 2). The expression of 
BDNF was measured at both mRNA and protein levels, and were via real-time polymerase chain 
reaction (RT-PCR), in situ hybridisation (ISH), western blotting (WB), immunohistochemistry 
(IHC), and enzyme-linked immunosorbent assays (ELISAs). The main brain regions studied 
included the hippocampus, prefrontal cortex (PFC), and dorsal striatum (dSTR), with a few studies 
on the nucleus accumbens (NAc) within the basal forebrain, and our own being the only one on the 
brainstem (Tang et al., 2008). The rationale for the study of these brain regions relates to the 
addictive nature of nicotine and interplay with the dopaminergic, glutamatergic and Gabaergic 
systems (PFC, dSTR and NAc) (Reviewed Feduccia et al., 2012), and the role of nicotine in 
affecting LTP (hippocampus) and respiratory control (brainstem). 
 
As shown in Table 2, the paradigms of nicotine exposure vary considerably including the age, dose, 
duration, and method of exposure. All these not surprisingly, lead to differing outcomes. In general, 
there is a consensus that BDNF expression increases after pre- and post-natal nicotine exposures in 
the NAc (Table 3), yet for the hippocampus, PFC and dSTR, an increase, decrease or no change in 
BDNF expression can occur (Table 3). Another contributing factor for the differences could be the 
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heterogeneous cell constituents and regions within each of these structures if they were studied on 
their own as shown by IHC and ISH, where specific subregional changes could be identified.  
 
The effect of nicotine exposure on TrkB expression (Table 4) 
The TrkB receptors have also been localised both pre- and post-synaptically, along axons, in 
synaptic terminals, and in the plasma membrane of dendritic spines and glial cells (Frisen et al., 
1993). The localization of TrkB in the synaptic terminal is consistent with the role of TrkB as a 
mediator of retrograde transport of BDNF to neuronal cell bodies (Murer et al., 2001).  
 
Much less has been reported regarding the effects of nicotine exposure on TrkB expression, with 
only 5 studies to date (summarised Table 4). All are in the adult brain (French et al., 1999, Sun et 
al., 2007, Formaggio et al., 2010, Xiao et al., 2015) with the exception of ours in the infant brains 
(Tang et al., 2008). The general finding seems to be increased TrkB expression in the hippocampus, 
cortex, and striatum (Table 3), but decreased levels in certain brainstem nuclei, the nucleus 
accumbens and the ventral tegmental area (Table 4).  
 
Mechanism(s) involved in nicotine induced BDNF and TrkB changes 
The expression of BDNF and TrkB are closely associated with nAChRs, however to date no studies 
have examined their colocalization. Evidence showing BDNF affecting nAChRs and vice versa 
predominantly relates to the α7 nAChRs. The injection of BDNF into cultured embryonic 
hippocampal (Massey et al., 2006) and adult cervical ganglionic neurons (Zhou et al., 2004) 
increased α7 nAChR expression, and increased the frequency of spontaneous synaptic currents 
within minutes (Zhou et al., 2004). Blocking α7 nAChRs leads to reduced BDNF mRNA 
expression in the hippocampus (Freedman et al., 1993). In contrast, exposing β2 nAChR knockout 
mice to nicotine had no effect on brain BDNF levels (Harrist et al., 2004). This suggests that the α4 
component of the α4β2 nAChRs is the predominating component interacting with BNDF after 
nicotine exposure. This is somewhat in line with the finding that almost all reported human studies 
of nicotine dependence found no association of the gene for the nAChR β2 subunit (CHRNB2) with 
nicotine dependence (Li et al., 2005, Feng et al., 2004, Silverman et al., 2000, Lueders et al., 2002) 
but did so for the α4 subunit gene (CHRNA4) (Li et al., 2005, Feng et al., 2004, Hutchison et al., 
2007). Subsequent analysis showed a strong interaction of CHRNA4 with BDNF and CHRNB2 
with TrkB (Li et al., 2008). 
 
Non-homology in BDNF and nAChRs expression changes have also been reported. In our 
laboratory using the infant piglet model of nicotine exposure, no change in BDNF protein 
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expression was observed in any of the brainstem nuclei studied (Tang et al., 2008) despite there 
being expression changes in α2, α3, α4, α7, α9, and β2 nAChR subunits (Vivekanandarajah et al., 
2015). The converse was reported by Romano et al. where they found nicotine exposure increased 
BDNF mRNA in the hippocampus and cortex, but had no effect on the nAChR subunits α2, α4, α7, 
and β2 (Romano et al., 2014). Thus, it remains in question whether the changes in BDNF 
expression after nicotine exposure are entirely dependent on nAChR activation and if so, via which 
subunits and to what level of activation.  
 
Based on the data and knowledge to date, we propose two mechanisms involved in nicotine induced 
changes of BDNF and TrkB (Figure 1). In the presence of nicotine, the nAChRs are activated, with 
the specific subunits dependent on the brain region. Upon binding, there is an influx of Ca2+  which 
causes an increased BDNF release with the precise mechanism still unknown, yet excitatory 
pathways via the n-methyl-d-aspartate receptor are implicated (Obrietan et al., 2002). This increases 
BDNF binding to TrKB, which leads to toxic levels of Ca2+ which then affects subsequent 
cascades that regulate cell survival and synaptic activity. Yet, nAChR desensitisation can occur 
with chronic nicotine exposures, thus reducing the activity of this pathway causing the opposite 
actions. A nAChR independent pathway is also feasible where nicotine causes direct epigenetic 
modifications to the BDNF gene which then affects the production of BDNF at both the mRNA and 
protein levels, thus decreasing the amount of BDNF release. For both mechanisms, a decrease in 
BDNF expression could be indicative of decreased neuroprotection to subsequent insults, or could 
be due to increased cell death. Increased BDNF expression could be indicative of increased 
neuroprotective mechanisms to counteract the ‘threat’. Increased TrkB expression seen in most 
paradigms of nicotine exposure would be indicative of an adaptation to balance BDNF changes to 
maintain normal homeostasis of cell survival and synaptic activity. 
 
Concluding remarks  
From this review, the majority of the paradigms involving nicotine exposure result in either 
increased or decreased BDNF expression, and mostly increased or no change in TrkB receptor 
expression (Summarised in Table 3). However, the majority of studies were undertaken in the adult 
rat and predominantly in the hippocampus and prefrontal cortex. Thus, further studies are required 
to determine the changes at other developmental stages, such as prenatal and early postnatal 
periods, and across other brain regions, particularly in regions of respiratory control and 
coordination of balance and movement as BDNF affects these specific motor controls. A better 
understanding of BDNF and TrkB change in such brain regions could be of clinical significance, 
given the long lasting effects of pre-natal nicotine exposure on addictive behaviour in the offspring 
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in adulthood (Kendler et al., 2012). This will facilitate breaking the cycle of smoking from the 
parents to the offspring.
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Figure Legends 
Figure 1. Schematic of (1) BDNF activation of TrkB and the regulation of this process by (2) 
nicotine. (1) BDNF binds to TrkB which activates and causes adjacently located TRPC3 channels 
to allow the influx of Na+ and Ca2+, as well as opens the sodium and calcium channels to allow the 
entry of these ions. The entry of Na+ causes the phosphorylation of TrkB which activates PLC 
which then activates IP3 leading to increased intracellular Ca2+ levels. (2) In the presence of 
nicotine, the nAChRs are activated, with the specific subunits dependent on the brain region. On 
binding, there is an influx of Ca2+ which causes increased BDNF release. This has positive 
feedback on pathway 1 leading to toxic levels of Ca2+ which then affects subsequent cascades 
regulating cell survival and synaptic activity. nAChR desensitisation can also occur, thus reducing 
this pathway causing opposite effects. A nAChR independent pathway is also feasible via 
epigenetic modification of the BDNF gene to affect the production of BDNF and pathway 1. 
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  Table 1- Human studies of nicotine exposure on BDNF system expression levels. 
Exposure regime 
Age & sex 




smokers (at least 
5 cigarettes/day 
for 9 years) 








Plasma, ELISA ↓ BDNF in 
smokers. 
Smoking 
cessation for 2 
months, ↑BDNF  
Kim et al., 2007 
Smokers, and 
week 4 & 12 of 
smoking 
cessation  





patch (n=21), & 
unaided (n=12). 
But only 19 
maintained until 
week 12. Thus 
n=19 for plasma 
levels at week 4 
and 12. 




at 4 and 12 









102 smokers vs 
37 non-smokers 
Serum ELISA ↑BDNF in 
schizophrenic 
smokers 
Zhang et al., 2010 






200 smokers vs 
111 non-smokers 











Suriyaprom et al., 
2013 









Serum, ELISA ↑BDNF in current 
smokers (both 
dependent and 
non having same 
levels) 




vs light smokers 
10 cigarettes/day 
14 smokers (7 
heavy, 7 light) vs 
13 non-smokers 




levels at night 
Neves et al., 2017 







 year of life 


















 year of life 
12 exposed to 
cigarette smoke 
vs 4 non-exposed 






Lavezzi et al., 
2014 
Fetus and Infants 
who died 
suddenly  




IHC for mature 
BDNF, 
cerebellum 
↓ BDNF in 
exposed 
Lavezzi et al., 
2018 
IHC, Immunohistochemistry, ND, nicotine dependence 
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Table 2 Summary of the effects of cigarette smoke and nicotine exposures on brain BDNF 




Method & Brain 
region 
Results References 




for 14 days 
Aged (22-24 













Adult male rat ISH;  
Hippocampus 
No change  French et al., 
1999 
Acute & Chronic 
exposure 
[injection twice 
daily, 7 days] 










daily, 7 days] 










Adult rat WB;  
Hippocampus 





minipump for 14 
days 
Infant piglet IHC,  
brainstem 




Infant (P8) mice ISH;  
Hippocampus 




for 5 weeks 





Czubak et al., 
2009 
12cigarettes/ 
day 7 days/week 
for 60 days 








for 7 weeks 












Neonatal (P5 & 




mRNA in males Damborsky and 
Winzer-Serhan 
2012 
3 mg/kg nicotine 
i.p. injections 6 
h before killing 
Adult male mice PCR- several bdnf 
transcripts; cortex 
mRNA Chase and 
Sharma 2013 
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Chronic low (6.3 









protein in high 
exposure 
Ortega et al., 
2013 
Oral nicotine  










mRNA Romano et al., 
2014 





Adult (P60)- mice RT-PCR & WB;  




Teen- no change 
Xiao et al., 2016 
Cigarette 
inhalation 
2x1hr/day  from 
P3-P14 









adult- no change 




2x1hr/day  & i.p 
nicotine 3-
9mg/kg/day 
short (4 weeks) 
vs long term (12 
weeks) 
Adult rat WB, IHC, cerebral 
cortex 
protein Naha et al., 2017 






(P35) female Rats  
RT-PCR & microarray; 
PFC, striatum, NAc, 
PVN, and the 
amygdala. 
 mRNA NAc & 
striatum,  PVN 
Wei et al., 2011 
0.05mg/kg/i.v. 
injection  3×/day 
from GD 8–21. 
weened P21 
Adolescence 
(P35) male & 
female rats 
ELISA; 
NAc, dSTR, PFC & 
hippocampus 
 protein all 
regions 










Adult (4 months) 
mice 
RT-PCR; WB;  
striatum 
mRNA & 










5 days  
Neonate-infancy 
male rat pups: 
group I P1-5,  
group II P5-10,  
group III P10-15. 
ELISA & WB; 
hippocampus & 
frontal cortex 
 in all groups for 
both regions 
Xiaoyu et al., 
2015 
Inhalation GD10 
for 10 days 




Xiao et al., 2016 




injection  3×/day 
from GD 8–21. 
weened P21 
Adult (P90) male 
& female mice 
ELISA; 
NAc, dSTR, PFC  
 protein NAc & 
dSTR,  in PFC 








protein Al-Sawalha et al., 
2017 
Abbreviations: dSTR, the dorsal striatum; ISH, in situ hybridisation; MALDI-TOF-MS, matrix-assisted laser 
desorption/ionization- Time of Flight- Mass Spectrometry; NAc, nucleus accumbens; PFC, prefrontal cortex; 
PVN, periventricular nucleus of the hypothalamus; RT-PCR, reverse transcription-polymerase chain 
reaction; WB, western blot.  
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Table 3: The number of studies in Table 2 and 4 that report an increase, decrease or (-) no change 
in BDNF and TrkB expression in the specific brain region studied.  
                                       BDNF 
                Postnatal                       Prenatal 
TrkB 
Postnatal 
Hippocampus 6 ↑ (4 mRNA, 2 protein) 
4 ↓ (3 mRNA, 2 protein) 
2 – (1 mRNA, 1 protein) 
1 ↑ (protein) 
3 ↓ (1 mRNA, 2 protein) 
 
3 ↑ (mRNA) 




4 ↑ (3 mRNA, 2 protein) 
2 – (2 mRNA, 2 protein) 
1 ↑ (protein) 
3 ↓ (1 mRNA, 2 protein) 
2 ↑ (3 mRNA, 1 protein) 
3 – (2 mRNA, 3 protein) 
Dorsal 
Striatum 
2 ↓ (1 mRNA, 2 protein) 
 
3 ↑ (1 mRNA, 2 protein) 
1 ↓ (mRNA & protein) 




1 ↑ (protein) 
 
3 ↑ (1 mRNA, 2 protein) 1 ↓ (mRNA & protein) 
1 – (mRNA & protein) 
Values in brackets indicate the changes that occur at the mRNA or protein level. Where the total is 
greater than the summary value, this indicates a study would have looked at both mRNA and 
protein. 
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Table 4: Summary of the effects of cigarette smoke and nicotine exposures on brain TrkB receptor 





Method & Brain region Results References 





Adult male rat ISH;  
Hippocampus 




mg/kg/day for 7 
days 
Adult rat RT-PCR; WB;  
PFC, Striatum, NAc, 







NAc & VTA 
protein in 
PFC, MBH,  
protein in 
NAc & VTA 





minipump for 14 
days 








RT-PCR; WB;  
Cerebral cortex, basal 
forebrain 
No change. Formaggio et al., 
2010 





Adult (P60)- mice RT-PCR & WB; 









Xiao et al., 2016 
Prenatal exposure    
Inhalation GD10 
for 10 days 
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